论文部分内容阅读
目的：探讨拉米夫定对于扰素无效的慢性乙型肝炎患者的疗效。方法：对２２例经干扰素治疗２０～２６周后无效的慢性乙型肝炎患者，用拉米夫定治疗，每日口服１００ｍｇ，共５２周。治疗前患者肝功能异常，ＨＢｓＡｇ、ＨＢｅＡｇ、抗－ＨＢｃ和 ＨＢＶ ＤＮＡ均阳性。治疗后３、６、９及１２月均对上述指标进行动态观察。结果：拉米夫定治疗一年后ＡＬＴ复常率８５％，无一例ＨＢｓＡｇ阴转，ＨＢｅＡｇ和ＨＢＶ ＤＮＡ阴转率分别为 ４０．９％（９／２２）和８１．８％（１８／２２），抗－ＨＢｅ阳转率 １８．２％（４／２２）。结论：经干扰素治疗无效后的慢性乙型肝炎患者，用拉米夫定治疗仍有效。
Objective: To investigate the curative effect of lamivudine on chronic hepatitis B patients with invalid interferon. Methods: Twenty-two patients with chronic hepatitis B who were inactive after 20-26 weeks of interferon treatment were treated with lamivudine orally for 100 weeks for 52 weeks. Patients with liver dysfunction before treatment, HBsAg, HBeAg, anti-HBc and HBV DNA were positive. 3,6,9 and 12 months after treatment, the above indicators were observed dynamically. Results: After one year of lamivudine treatment, the recovery rate of ALT was 85%. None of the cases had HBsAg negative conversion. The negative conversion rates of HBeAg and HBV DNA were 40.9% (9/22) and 81.8% (18/22 ), Anti-HBe positive rate of 18.2% (4/22). CONCLUSIONS: Chronic hepatitis B patients who fail to respond to interferon are still treated with lamivudine.